Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H22FN3O8 |
Molecular Weight | 439.3917 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC(=CC(OC)=C1OC)C(=O)NC2=NC(=O)N(C=C2F)[C@@H]3O[C@H](C)[C@@H](O)[C@H]3O
InChI
InChIKey=TVYPSLDUBVTDIS-FUOMVGGVSA-N
InChI=1S/C19H22FN3O8/c1-8-13(24)14(25)18(31-8)23-7-10(20)16(22-19(23)27)21-17(26)9-5-11(28-2)15(30-4)12(6-9)29-3/h5-8,13-14,18,24-25H,1-4H3,(H,21,22,26,27)/t8-,13-,14-,18-/m1/s1
Molecular Formula | C19H22FN3O8 |
Molecular Weight | 439.3917 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Galocitabine is an orally available 5-fluorouracil (5-FU) prodrug with potential antineoplastic activity. Upon administration, galocitabine is converted to 5’-deoxy-fluorocytidine (5’-DFCR) by acylamidase in the liver and is then converted to 5’-DFUR by cytidine deaminase. Efficient conversion of galocitabine to 5-FU is necessary for galocitabine to have a therapeutic effect. 5-FU is further metabolized into other cytotoxic metabolites that interfere with RNA and DNA synthesis via inhibition of thymidylate synthase. As a result, this agent eventually inhibits tumor cell growth.
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:37:05 GMT 2023
by
admin
on
Fri Dec 15 15:37:05 GMT 2023
|
Record UNII |
X9788XI79O
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1557
Created by
admin on Fri Dec 15 15:37:05 GMT 2023 , Edited by admin on Fri Dec 15 15:37:05 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000084513
Created by
admin on Fri Dec 15 15:37:05 GMT 2023 , Edited by admin on Fri Dec 15 15:37:05 GMT 2023
|
PRIMARY | |||
|
X9788XI79O
Created by
admin on Fri Dec 15 15:37:05 GMT 2023 , Edited by admin on Fri Dec 15 15:37:05 GMT 2023
|
PRIMARY | |||
|
6806
Created by
admin on Fri Dec 15 15:37:05 GMT 2023 , Edited by admin on Fri Dec 15 15:37:05 GMT 2023
|
PRIMARY | |||
|
65950
Created by
admin on Fri Dec 15 15:37:05 GMT 2023 , Edited by admin on Fri Dec 15 15:37:05 GMT 2023
|
PRIMARY | |||
|
DTXSID10154189
Created by
admin on Fri Dec 15 15:37:05 GMT 2023 , Edited by admin on Fri Dec 15 15:37:05 GMT 2023
|
PRIMARY | |||
|
C73254
Created by
admin on Fri Dec 15 15:37:05 GMT 2023 , Edited by admin on Fri Dec 15 15:37:05 GMT 2023
|
PRIMARY | |||
|
CHEMBL2106813
Created by
admin on Fri Dec 15 15:37:05 GMT 2023 , Edited by admin on Fri Dec 15 15:37:05 GMT 2023
|
PRIMARY | |||
|
124012-42-6
Created by
admin on Fri Dec 15 15:37:05 GMT 2023 , Edited by admin on Fri Dec 15 15:37:05 GMT 2023
|
PRIMARY | |||
|
SUB07875MIG
Created by
admin on Fri Dec 15 15:37:05 GMT 2023 , Edited by admin on Fri Dec 15 15:37:05 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |